Patents by Inventor Helmut Jonuleit

Helmut Jonuleit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • In-vitro methods for the detection of autoimmune diseases or conditions
    Patent number: 11447825
    Abstract: A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 20, 2022
    Assignee: Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Bettina Trinschek, Kazuki Satoh, Helmut Jonuleit
  • Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
    Publication number: 20200316167
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 8, 2020
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
    Patent number: 10729742
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: August 4, 2020
    Assignee: Universitätsmedizin Der Johannes Gutenberg-Universität Mainz
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • In-vitro methods for the detection of autoimmune diseases or conditions
    Publication number: 20180216186
    Abstract: A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls.
    Type: Application
    Filed: August 9, 2016
    Publication date: August 2, 2018
    Inventors: Bettina Trinschek, Kazuki Satoh, Helmut Jonuleit
  • Humanized anti-CD4 antibody with immunosuppressive properties
    Patent number: 9758581
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: September 12, 2017
    Assignee: BIOTEST AG
    Inventors: John Wijdenes, Helmut Jonuleit
  • SCREENING METHOD FOR THE IDENTIFICATION OF AGENTS CAPABLE OF ACTIVATING CD4+CD25+ REGULATORY T-CELLS THROUGH INTERACTIONS WITH THE HIV-1 GP120 BINDING SITE ON CD4
    Publication number: 20170014474
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 19, 2017
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Humanized Anti-CD4 Antibody With Immunosuppressive Properties
    Publication number: 20140220008
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 7, 2014
    Applicant: BIOTEST AG
    Inventors: John Wijdenes, Helmut Jonuleit
  • Screening Method for the Identification of Agents Capable of Activating CD4+CD25+ Regulatory T-Cells Through Interactions with the HIV-1 GP120 Binding Site on CD4
    Publication number: 20140093509
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Application
    Filed: September 19, 2013
    Publication date: April 3, 2014
    Applicant: TCF GMBH
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Method for screening for an anti-CD4 antibody suitable for use in immunotherapy
    Patent number: 8685651
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: April 1, 2014
    Assignee: Biotest AG
    Inventors: John Wijdenes, Helmut Jonuleit
  • Humanized anti-CD4 antibody with immunosuppressive properties
    Patent number: 8673304
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: March 18, 2014
    Assignee: Biotest AG
    Inventors: John Wijdenes, Helmut Jonuleit
  • Humanized anti-CD4 antibody with immunosuppressive properties
    Patent number: 8586715
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: November 19, 2013
    Assignee: Biotest AG
    Inventors: John Wijdenes, Helmut Jonuleit
  • Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
    Patent number: 8557533
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: October 15, 2013
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Humanized anti-CD4 antibody with immunosuppressive properties
    Patent number: 8440806
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: May 14, 2013
    Assignee: Biotest AG
    Inventors: John Wijdenes, Helmut Jonuleit
  • HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES
    Publication number: 20100291676
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Application
    Filed: February 25, 2009
    Publication date: November 18, 2010
    Inventors: JOHN WIJDENES, HELMUT JONULEIT
  • SPECIFIC ACTIVATION OF A REGULATORY T CELL AND ITS USE FOR TREATMENT OF ASTHMA, ALLERGIC DISEASE, AUTOIMMUNE DISEASE, GRAFT REJECTION AND FOR TOLERANCE INDUCTION
    Publication number: 20100074904
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Application
    Filed: January 30, 2008
    Publication date: March 25, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES
    Publication number: 20090208497
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Application
    Filed: February 25, 2009
    Publication date: August 20, 2009
    Inventors: John Wijdenes, Helmut Jonuleit
  • HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES
    Publication number: 20090208496
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Application
    Filed: February 25, 2009
    Publication date: August 20, 2009
    Inventors: John Wijdenes, Helmut Jonuleit
  • HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES
    Publication number: 20090104190
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Application
    Filed: October 7, 2008
    Publication date: April 23, 2009
    Inventors: John Wijdenes, Helmut Jonuleit
  • Humanized anti-CD4 antibody with immunosuppressive properties
    Patent number: 7452981
    Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: November 18, 2008
    Assignee: Biotest AG
    Inventors: John Wijdenes, Helmut Jonuleit
  • Regulatory T-Cells Containing Galectins for the Therapy and Diagnosis of Diseases
    Publication number: 20080118515
    Abstract: The invention relates to regulator T-cells containing galectins, in particular, the use thereof as markers and for the therapy and diagnosis of diseases, in particular, of allergies and autoimmune diseases, in particular rheumatoid arthritis, multiple sclerosis or Crohn's disease, chronic inflammation, asthma, immune deficiency diseases, AIDS, transplant rejection, cancer diseases and diabetes.
    Type: Application
    Filed: July 15, 2004
    Publication date: May 22, 2008
    Applicant: PROTAGEN AG
    Inventors: Petra Lutter, Petra Weingarten, Christoph Huels, Hemut E. Meyer, Edgar Schmitt, Helmut Jonuleit